Tirzepatide acts on two hormone receptors rather than one, and the same molecule is sold for weight management under the name Zepbound.1
What it is
The label describes Mounjaro as a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist.1 In plain terms it copies two gut hormones that are released after eating. Semaglutide, the molecule in Ozempic and Wegovy, acts only on the GLP-1 receptor, which is why tirzepatide is often called a dual agonist.
Its half-life is about 5 days, so one injection a week keeps a steady level in the blood once the dose is stable.1 It is injected under the skin of the abdomen or thigh, or by another person into the back of the upper arm, at any time of day and with or without meals. The label asks for a different injection site with each dose.1
How the dose climbs
Treatment starts at 2.5 mg once a week. After 4 weeks the dose goes to 5 mg, and if more blood sugar control is needed it rises in steps of 2.5 mg, each after at least 4 weeks on the current dose. The maximum is 15 mg a week for adults and 10 mg for children aged 10 and older.1 At the fastest pace the label allows, an adult reaches 15 mg in week 21. Our page on the Mounjaro dosing schedule puts the steps on a calendar.
What it did in trials
In the label's 40-week trial of Mounjaro on its own, in adults whose diabetes was not controlled by diet and exercise, HbA1c started at about 8%. It fell by 1.8 points on 5 mg and 1.7 on 10 mg and 15 mg, against 0.1 on placebo. An HbA1c under 7% was reached by 82%, 85% and 78% on the three doses, against 23% on placebo. Weight fell by 6.3, 7.0 and 7.8 kg, against 1.0 kg on placebo.1
The comparison most people ask about is the 40-week trial against semaglutide 1 mg, the dose of Ozempic used at the time, in adults already taking metformin. Starting from an HbA1c of 8.3%, it fell by 2.0, 2.2 and 2.3 points on Mounjaro 5, 10 and 15 mg, against 1.9 on semaglutide. Weight fell by 7.6, 9.3 and 11.2 kg, against 5.7 kg.1 Ozempic now goes up to 2 mg, a dose that trial did not test, so the gap applies to the 1 mg dose only. Our page on Ozempic and Mounjaro compares the two labels in full.
Side effects and warnings
The most common side effects are nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion and abdominal pain. In the label's placebo-controlled trials, nausea was reported by 12%, 15% and 18% on 5, 10 and 15 mg, against 4% on placebo, and diarrhea by 12%, 13% and 17%, against 9%.1 Our page on Mounjaro side effects sets out when they start and how long they last.
Mounjaro carries the same boxed warning about thyroid C-cell tumors as the semaglutide brands and must not be used by people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2.1 Two practical points are easy to miss. The label advises people on birth control pills to switch to a non-oral method, or add a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase. The reason is slower stomach emptying, which may make the pill less effective; the label says this delay is largest after the first dose and shrinks over time.1 It also lists low blood sugar as a risk when Mounjaro is combined with insulin or a sulfonylurea.1
Mounjaro in eight lines
| Fact | Mounjaro |
|---|---|
| Active ingredient | Tirzepatide |
| Maker | Eli Lilly |
| First U.S. approval | 2022 |
| Receptors | GIP and GLP-1 |
| How often | Once a week, under the skin |
| Doses | 2.5 mg to start, up to 15 mg |
| Half-life | About 5 days |
| Approved for weight loss | No, that is Zepbound |
MOUNJARO prescribing information, revised April 2026.1
Related terms
Zepbound contains the same tirzepatide in the same doses, approved for weight and for obstructive sleep apnea in adults with obesity; the label of each says not to combine it with another tirzepatide product or with a GLP-1 receptor agonist.2 Our page on Mounjaro and Zepbound explains where the two labels part.
Sources
- MOUNJARO (tirzepatide) prescribing information, NDA 215866/S-052, revised April 2026. U.S. Food and Drug Administration; sections 1, 2, 4, 5, 6.1, 7, 8.3, 12 and 14. accessdata.fda.gov
- ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; section 1. accessdata.fda.gov
Related analyses
Mounjaro dosing schedule: 2.5 mg to 15 mg, week by week, with your own dates
Mounjaro side effects: how common each one is by dose, and when they ease
Ozempic vs Mounjaro: what the head-to-head trial and the two labels show
Mounjaro vs Zepbound: the same drug under two labels, compared by use, results and price
Log each Mounjaro dose and see your week, levels and symptoms together.
Open Dose Insider